Article info

Original research
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Authors

  1. Correspondence to Professor Weidong Han; hanwdrsw69{at}yahoo.com; Professor Jing Nie; nnjj2002{at}163.com
View Full Text

Citation

Liu Y, Wang C, Li X, et al
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Publication history

  • Accepted March 9, 2021
  • First published April 5, 2021.
Online issue publication 
April 05, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.